Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Acad Med ; 96(11): 1529-1533, 2021 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-33983136

RESUMO

The COVID-19 crisis has seriously affected academic medical centers (AMCs) on multiple levels. Combined with many trends that were already under way pre pandemic, the current situation has generated significant disruption and underscored the need for change within and across AMCs. In this article, the authors explore some of the major issues and propose actionable solutions in 3 areas of concentration. First, the impact on medical students is considered, particularly the trade-offs associated with online learning and the need to place greater pedagogical emphasis on virtual care delivery and other skills that will be increasingly in demand. Solutions described include greater utilization of technology, building more public health knowledge into the curriculum, and partnering with a wide range of academic disciplines. Second, leadership recruiting, vital to long-term success for AMCs, has been complicated by the crisis. Pressures discussed include adapting to the dynamics of competitive physician labor markets as well as attracting candidates with the skill sets to meet the requirements of a shifting AMC leadership landscape. Solutions proposed in this domain include making search processes more focused and streamlined, prioritizing creativity and flexibility as core management capabilities to be sought, and enhancing efforts with assistance from outside advisors. Finally, attention is devoted to the severe financial impact wrought by the pandemic, creating challenges whose resolution is central to planning future AMC directions. Specific challenges include recovery of lost clinical revenue and cash flow, determining how to deal with research funding, and the precarious economic balancing act engendered by the need to continue distance education. A full embrace of telehealth, collaborative policy-making among the many AMC constituencies, and committing fully to being in the vanguard of the transition to value-based care form the solution set offered.


Assuntos
Centros Médicos Acadêmicos/organização & administração , COVID-19/psicologia , Atenção à Saúde/tendências , Estudantes de Medicina/psicologia , Centros Médicos Acadêmicos/economia , Tecnologia Biomédica/instrumentação , COVID-19/diagnóstico , COVID-19/epidemiologia , COVID-19/virologia , Educação Baseada em Competências/métodos , Criatividade , Educação a Distância/métodos , Educação de Pós-Graduação em Medicina/economia , Humanos , Liderança , Formulação de Políticas , SARS-CoV-2/genética , Telemedicina
5.
Ann Intern Med ; 150(7): 493-5, 2009 Apr 07.
Artigo em Inglês | MEDLINE | ID: mdl-19258550

RESUMO

The coverage, cost, and quality problems of the U.S. health care system are evident. Sustainable health care reform must go beyond financing expanded access to care to substantially changing the organization and delivery of care. The FRESH-Thinking Project (www.fresh-thinking.org) held a series of workshops during which physicians, health policy experts, health insurance executives, business leaders, hospital administrators, economists, and others who represent diverse perspectives came together. This group agreed that the following 8 recommendations are fundamental to successful reform: 1. Replace the current fee-for-service payment system with a payment system that encourages and rewards innovation in the efficient delivery of quality care. The new payment system should invest in the development of outcome measures to guide payment. 2. Establish a securely funded, independent agency to sponsor and evaluate research on the comparative effectiveness of drugs, devices, and other medical interventions. 3. Simplify and rationalize federal and state laws and regulations to facilitate organizational innovation, support care coordination, and streamline financial and administrative functions. 4. Develop a health information technology infrastructure with national standards of interoperability to promote data exchange. 5. Create a national health database with the participation of all payers, delivery systems, and others who own health care data. Agree on methods to make de-identified information from this database on clinical interventions, patient outcomes, and costs available to researchers. 6. Identify revenue sources, including a cap on the tax exclusion of employer-based health insurance, to subsidize health care coverage with the goal of insuring all Americans. 7. Create state or regional insurance exchanges to pool risk, so that Americans without access to employer-based or other group insurance could obtain a standard benefits package through these exchanges. Employers should also be allowed to participate in these exchanges for their employees' coverage. 8. Create a health coverage board with broad stakeholder representation to determine and periodically update the affordable standard benefit package available through state or regional insurance exchanges.


Assuntos
Reforma dos Serviços de Saúde/organização & administração , Cobertura Universal do Seguro de Saúde/organização & administração , Regulamentação Governamental , Reforma dos Serviços de Saúde/economia , Humanos , Reembolso de Seguro de Saúde/economia , Gestão da Qualidade Total/economia , Estados Unidos , Cobertura Universal do Seguro de Saúde/economia
6.
Cleve Clin J Med ; 74 Suppl 2: S10-1; discussion 16-22, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17469467

RESUMO

Industry's interaction with academia has created vast opportunity for innovation but also the potential for undue financial influence. Potential conflicts of interest can occur at the level of the individual researcher or the institution. Implementing guidelines and policies on conflicts of interest can help maintain appropriate separation between academic medicine and industry while permitting medical innovation to proceed. In an effort to retain public trust, Stanford University School of Medicine has enacted policies to identify and manage potential conflicts among its faculty, to divest of holdings in companies conducting studies involving Stanford investigators, and to ban all industry marketing and gifts from Stanford facilities.


Assuntos
Centros Médicos Acadêmicos/ética , Pesquisa Biomédica/ética , Conflito de Interesses , Empreendedorismo/ética , Docentes de Medicina/normas , Setor de Assistência à Saúde/ética , Centros Médicos Acadêmicos/economia , Pesquisa Biomédica/economia , California , Difusão de Inovações , Empreendedorismo/economia , Humanos , Confiança
8.
Cancer Invest ; 20(3): 420-33, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12025236

RESUMO

For over 30 years, fever and neutropenia in cancer patients has been treated with the utmost urgency, necessitating inpatient evaluation and immediate initiation of empirical broad-spectrum parenteral (i.v.) antibiotics. This practice is based on the recognition that delays in starting antibiotic therapy in febrile neutropenic patients have been associated with life-threatening infections and sometimes fatal consequences. Over the past decade, it has become evident that neutropenic cancer patients are not a homogeneous group and that practice guidelines may vary on their risk status. In fact, attempts have been made to stratify patients into high-risk and low-risk groups and differentiate treatment options respectively. Recent studies suggest that those neutropenic cancer patients who are at low risk may even be successfully treated with oral therapy, thus opening the possibility for ambulatory or home-based management. Oral antibiotic therapy, especially if safely delivered at home, offers a number of advantages including lower cost, improved quality of life (although the impact of shifting the burden of care from the hospital to the home setting on the patient, parent or care provider needs careful assessment) and a decreased risk for nosocomial infection.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Neutropenia/induzido quimicamente , Neutropenia/tratamento farmacológico , Guias de Prática Clínica como Assunto , Administração Oral , Assistência Ambulatorial , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Controle de Custos , Infecção Hospitalar/prevenção & controle , Febre/induzido quimicamente , Humanos , Infusões Intravenosas , Neoplasias/tratamento farmacológico , Qualidade de Vida , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA